CanSinoBIO inhaled Covid vaccine candidate triggers immune response - early trial
An inhaled version of CanSino Biologics' (CanSinoBIO) Covid-19 vaccine triggered immune responses without serious side effects, an early-stage clinical trial showed.
The two-dose candidate requires lower dosages than the injected version and could help CanSinoBIO boost its production capacity, the company's chief executive said in April.
Two inhaled doses of the Ad5-nCoV vaccine, given 28 days apart, elicited...
Verifying user
RM12.50 / month
- Unlimited access to award-winning journalism
- Comment and share your opinions on all our articles
- Gift interesting stories to your friends
- Tax deductable